Transgene Website, Blog & Press Pages

Transgene Website, Blog & Press Pages - aVenture Research

Library

transgene.comCrawled Nov 10, 2026

Product

6 pages

Advancing Our Pipeline/advancing-our-pipeline
Myvac Tm Viral Based Vaccine for Personalized Neoantigen Directed Cancer Therapy/myvac-tm-viral-based-vaccine-for-personalized-neoantigen-directed-cancer-therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation
Pipeline/pipeline
It has been evaluated in a Phase 1/2a multicenter, open label, dose-escalation study as a single agent and in combination with pembrolizumab* in solid tumors after intratumoral administration.
Produits Tg4050 Teaser/produits-tg4050-teaser
TG4050 is an Individualized Neoantigen Therapeutic Vaccine and the first asset from myvac platform.

Blog

6 pages

130 a Multivalent Adenovirus Based Immunotherapeutic for Treatment of Chronic Hepatitis B Induces Broad Robust and Polyfunctional T Cells in Naive and Hbv Tolerant Mice/130-a-multivalent-adenovirus-based-immunotherapeutic-for-treatment-of-chronic-hepatitis-b-induces-broad-robust-and-polyfunctional-t-cells-in-naive-and-hbv-tolerant-mice
Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article Publication
33 Tg1050 a Viral Vector Based Immunotherapeutic Designed to Treat Chronic Hepatitis B Induces Immune Responses Similar to Those Display by Hbv Resolving Patients and Has an Early Antiviral/33-tg1050-a-viral-vector-based-immunotherapeutic-designed-to-treat-chronic-hepatitis-b-induces-immune-responses-similar-to-those-display-by-hbv-resolving-patients-and-has-an-early-antiviral
Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – Download the article Publication
Comparative Analysis of Immunization Schedules Using a Novel Adenovirus Based Immunotherapeutic Targeting Hepatitis B in Naive and Tolerant Mouse Models/comparative-analysis-of-immunization-schedules-using-a-novel-adenovirus-based-immunotherapeutic-targeting-hepatitis-b-in-naive-and-tolerant-mouse-models
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators/fluorescent-tagged-vaccinia-virus-genome-allows-rapid-and-efficient-measurement-of-oncolytic-potential-and-discovery-of-oncolytic-modulators
Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Press

6 pages

June 17th 2014 Letter to Shareholders/june-17th-2014-letter-to-shareholders
Time a Phase 2b3 Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer Nsclc Phase 2B Results/time-a-phase-2b3-evaluating-tg4010-in-combination-with-first-line-therapy-in-advanced-non-small-cell-lung-cancer-nsclc-phase-2b-results
ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Transgene Announces Third Quarter 2014 Financial Results/transgene-announces-third-quarter-2014-financial-results
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on Tg4010 2/transgene-reports-financial-results-for-first-six-months-of-2014-and-provides-update-on-tg4010-2

Team

6 pages

Christophe Ancel/christophe-ancel
Christophe Ancel, PharmD, has served as Vice President, Pharmaceutical Operations and responsible pharmacist since 2008. He had joined Transgene as Head of quality Insurance in 1998.
Composition of the Board of Directors and Statutory Auditors/composition-of-the-board-of-directors-and-statutory-auditors
John Felitti/john-felitti
John Felitti has been Transgene’s General Counsel & Corporate Secretary since 2016. Before joining, he held roles in legal, finance, and securities law at Sanofi and Aventis, and practiced law in Paris from 1996 to 2003.
Lucie Larguier/lucie-larguier
Lucie Larguier became Chief Financial Officer in 2024 after serving as VP of Corporate Communication and Investor Relations since 2023. She previously led corporate communications and investor relations from 2016 to 2023 and worked in financial and corporate communications for over 10 years.

About

2 pages

Corporate Presentation/corporate-presentation
Transgene corporate presentation_3 December 2014
Key Figures/key-figures
In € million except share and per share data

Contact

1 page

FAQ/faq
Clinical trials are designed to evaluate new treatments, including their safety and efficacy. They are mandatory before approval and commercialization of new treatments.

Homepage

1 page

Homepage/
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer

Coverage

6 items

Transgene shares gain 3% with financial visibility until 2028ideal-investisseur.fr/en/stock-news/transgene-shares-gain-3-with-financial-visibility-until-2028/29097.html
Transgene’s stock rises **3.12% to €0.76** amid updated financial guidance extending to 2028. The company trades **7% above its 20-day moving average (MM20)** but remains **36% below its year-ago level**. Technical indicators show neutral momentum, with resistance near €0.778 and the 200-day moving average (MM200) acting as a near-term hurdle.
Nov 2026Idéal InvestisseurNews article
Neoantigen vaccine shows encouraging activity in head and neck cancercancernetwork.com/view/neoantigen-vaccine-shows-encouraging-activity-in-head-and-neck-cancer
A phase 1 trial of the MVA-vectored neoantigen vaccine **TG4050** demonstrates no dose-limiting toxicities or disease relapses in patients with resected, HPV-negative head and neck squamous cell carcinoma (HNSCC). The vaccine targets personalized neoantigens to stimulate an immune response without observed adverse effects in early testing. Researchers highlight its potential as a therapeutic approach for this cancer subtype.
Sep 2026CancerNetworkNews article
100% three-year disease-free survival in head and neck cancerddw-online.com/100-three-year-disease-free-survival-in-head-and-neck-cancer-43759-202609/
Transgene and NEC Corporation report 100% three-year disease-free survival in patients treated with TG4050 in the Phase I portion of a randomized Phase I/II trial. The results demonstrate sustained efficacy for the therapy in head and neck cancer patients. This milestone follows testing in a controlled clinical setting.
Sep 2026Drug Discovery WorldNews article
Transgene completes initial Phase II screening of TG4050 in head and neck cancerclinicaltrialsarena.com/news/transgene-tg4050-trial/
Transgene finishes screening patients for the Phase II portion of its Phase I/II trial testing **TG4050**, a personalized neoantigen vaccine for **HPV-negative squamous head and neck cancer**. The vaccine is being evaluated as a standalone adjuvant treatment in this study. The trial follows a prior Phase I assessment of the therapy’s safety and efficacy.
Jun 2025Clinical Trials ArenaNews article